Urological Research

, Volume 33, Issue 2, pp 116–124

Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial

Original Paper


The purpose of this study was to investigate the prophylactic and therapeutic effects of a hitherto untested preparation containing sodium citrate in the management of calcium oxalate urolithiasis. In this study, a host of calcium oxalate kidney stone risk factors was investigated using a randomised, placebo controlled, “within-patient” clinical trial. The trial involved four groups of subjects: healthy male controls, healthy female controls , calcium oxalate stone-forming males and calcium oxalate stone-forming females. There were 30 subjects in each group. Twenty subjects in each group ingested the preparation containing sodium citrate and ten subjects in each group ingested a placebo for 7 days. Collection of 24 h urines were carried out at baseline, at day 7 and day 10 (i.e. 3 days after suspension of drug/placebo ingestion). These were analysed for biochemical and physicochemical risk factors. They were also tested for their inhibitory properties in crystallization experiments. Data were statistically analyzed using analysis of variance (ANOVA). Key risk factors were significantly and beneficially altered across all groups after ingestion of the preparation. The pH and urinary citrate excretion increased while urinary oxalate and calcium excretions decreased, as did relative supersaturations of calcium oxalate and uric acid. In addition, inhibition of calcium oxalate crystallization increased. Beneficial carryover effects were observed for some risk factors. The results of this study have demonstrated, for the first time, that a sodium citrate-containing preparation favourably alters the risk factors for calcium oxalate urolithiasis.


Calcium oxalate urolithiasis Prophylactics Therapy Randomized, placebo-controlled trial Sodium-citrate-bicarbonate-tartrate 


  1. 1.
    Pak CYC (1987) Citrate and renal calculi. Miner Electrolyte Metab 13: 257PubMedGoogle Scholar
  2. 2.
    Pak CYC (1991) Citrate and renal calculi: new insights and future directions. Am J Kidney Dis 17: 420PubMedGoogle Scholar
  3. 3.
    Pak CYC (1994) Citrate and renal calculi: an update. Miner Electrolyte Metab 20: 371PubMedGoogle Scholar
  4. 4.
    Hallson PC, Rose GA, Sulaiman S (1983) Raising urinary citrate lowers calcium oxalate and calcium phosphate crystal formation in whole urine. Urol Int 38: 179PubMedGoogle Scholar
  5. 5.
    Nicar MJ, Hill K, Pak CYC (1987) Inhibition by citrate of spontaneous precipitation of calcium oxalate in vitro. J Bone Min Res 2: 215Google Scholar
  6. 6.
    Schwille PO, Schmiedl A, Herrmann U, Fan J, Gottlieb D, Manoharan M et al. (1999) Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 27: 117PubMedGoogle Scholar
  7. 7.
    Ryall RL, Harnett RM, Marshall VR (1981) The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 112: 349PubMedGoogle Scholar
  8. 8.
    Bek-Jensen H, Fornander A-M, Nilsson M-A, Tiselius H-G (1996) Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine? Urol Res 24: 67PubMedGoogle Scholar
  9. 9.
    Kok DJ, Papapoulos SE, Bijvoet OLM (1986) Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1056Google Scholar
  10. 10.
    Kok DJ, Papapoulos SE, Bijvoet OLM (1987) Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers. Contr Nephrol 58: 73Google Scholar
  11. 11.
    Tiselius H-G, Fornander A-M, Nilsson M-A (1993) The effects of citrate and urine on calcium oxalate crystal aggregation. Urol Res 21: 363PubMedGoogle Scholar
  12. 12.
    Rudman D, Kutner MH, Redd SC, Waters WC, Gerron GG, Bleier J (1982) Hypocitraturia in calcium nephrolithiasis. J Clin Endocrinol Metab 55: 1052PubMedGoogle Scholar
  13. 13.
    Nicar MJ, Skurla C, Sakhaee K, Pak CYC (1983) Low urinary citrate excretion in nephrolithiasis. Urology 21: 8PubMedGoogle Scholar
  14. 14.
    Hosking DH, Wilson JWL, Liedtke RR, Smith LH, Wilson DM (1985) Urinary citrate excretion in normal persons and patients with idiopathic calcium urolithiasis. J Lab Clin Med 106: 682PubMedGoogle Scholar
  15. 15.
    Laminski NA, Meyers AM, Sonnekus MI, Smyth AE (1990) Prevalence of hypocitraturia and hypopyrophosphaturia in recurrent calcium stone formers: as isolated defects or associated with other metabolic abnormalities. Nephron 56: 379PubMedGoogle Scholar
  16. 16.
    Cupisti A, Morelli E, Lupetti S, Meola M, Barsotti G (1992) Low urine citrate excretion as main risk factor for recurrent calcium oxalate nephrolithiasis in males. Nephron 61: 73PubMedGoogle Scholar
  17. 17.
    Pak CYC, Fuller C, Sakhaee K, Preminger GM, Britton F (1985) Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 134: 11PubMedGoogle Scholar
  18. 18.
    Pak CYC, Fuller C (1986) Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate. Ann Intern Med 104: 33PubMedGoogle Scholar
  19. 19.
    Abdulhadi MH, Hall PM, Streem SB (1993). Can citrate therapy prevent nephrolithiasis? Urology 41: 221PubMedGoogle Scholar
  20. 20.
    Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CYC (1993) Randomized double-blinded study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150: 1761PubMedGoogle Scholar
  21. 21.
    Whalley NA, Meyers AM, Martins M, Margolius LP (1996) Long-term effects of potassium citrate therapy on the formation of new stones in groups of recurrent stone formers with hypocitraturia. Br J Urol 78: 10PubMedGoogle Scholar
  22. 22.
    Schwille PO, Weippert JH, Bausch W, Rumenapf G (1985) Acute oral alkali citrate load in healthy humans—response of blood and urinary citrate, mineral metabolism, and factors related to stone formation. Urol Res 13: 161PubMedGoogle Scholar
  23. 23.
    Schwille PO, Rumenapf G, Kohler R, Sorgel F (1987) Effects of acute oral sodium potassium citrate load in healthy males-outlook for treatment of patients with calcium-containing renal stones. Urol Int 42: 81PubMedGoogle Scholar
  24. 24.
    Rumenapf G, Schwille PO (1987) The influence of oral alkali citrate on intestinal calcium absorption in healthy man. Clin Sci 73: 117PubMedGoogle Scholar
  25. 25.
    Berg C, Larsson L, Tiselius H-G (1990) Effects of different doses of alkaline citrate on urine composition and crystallization of calcium oxalate. Urol Res 18: 13PubMedGoogle Scholar
  26. 26.
    Hofbauer J, Hobarth K, Szabo N, Marberger M (1994) Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis—a prospective randomized study. Br J Urol 73: 362PubMedGoogle Scholar
  27. 27.
    Ogawa Y (1994) Impact of sodium-potassium citrate on the diurnal variations in urinary calcium oxalate and calcium phosphate saturation levels in normal individuals. Br J Urol 73: 136PubMedGoogle Scholar
  28. 28.
    Sakhaee K, Baker S, Zerwekh J, Poindexter J, Garcia-Hernandez PA, Pak CYC (1994) Limited risk of kidney stone formation during long-term calcium citrate supplementation in nonstone forming subjects. J Urol 152: 324PubMedGoogle Scholar
  29. 29.
    Levine BS, Rodman JS, Wienerman S, Bockman RS, Lane JM (1994) Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: implications for prevention of osteoporosis. Am J Clin Nutr 60: 592PubMedGoogle Scholar
  30. 30.
    Schwille PO, Schmiedl A, Herrmann U, Schwille R, Fink E, Manoharan M (1997) Acute oral calcium-sodium citrate load in healthy males. Effects on acid-base and mineral metabolism, oxalate and other risk factors of stone formation in urine. Methods Find Exp Clin Pharmacol 19: 417PubMedGoogle Scholar
  31. 31.
    Pak CYC, Koenig K, Khan R, Haynes S, Padalino P (1992) Physicochemical action of potassium-magnesium citrate in nephrolithiasis. J Bone Miner Res 7(3): 281PubMedGoogle Scholar
  32. 32.
    Ettinger B, Pak CYC, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158:2069PubMedGoogle Scholar
  33. 33.
    Ito H, Suzuki F, Yamaguchi K, Nishikawa Y, Kotake T (1992). Reduction of urinary oxalate by combined calcium and citrate administration without increase in urinary calcium oxalate stone formers. Clin Nephrol 37: 14PubMedGoogle Scholar
  34. 34.
    Sakhaee K, Nicar M, Hill K, Pak CYC (1983) Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 24: 348PubMedGoogle Scholar
  35. 35.
    Preminger GM, Sakhaee K, Pak CYC (1988) Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol 139: 240PubMedGoogle Scholar
  36. 36.
    Sakhaee K, Nicar M, Jacobson H, Pak CYC (1982) Potassium alkali therapy of uric acid lithiasis may prevent complication of calcium stones (abstract). Clin Res 30: 403AGoogle Scholar
  37. 37.
    Pak CYC, Sakhaee K, Fuller C (1986) Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 30: 422PubMedGoogle Scholar
  38. 38.
    Allie S, Rodgers A (2003) Effects of calcium carbonate, magnesium oxide and sodium citrate bicarbonate health supplements on the urinary risk factors for kidney stone formation. Clin Chem Lab Med 41: 39PubMedGoogle Scholar
  39. 39.
    Fernandez FJ, Kahn HL (1971) Clinical methods for atomic absorption Spectroscopy. Clin Chem Newslett 3: 24Google Scholar
  40. 40.
    Trudeau DL, Freier EF (1967) Determination of calcium in urine and serum by atomic absorption spectrophotometry (AAS). Clin Chem 13: 101PubMedGoogle Scholar
  41. 41.
    Willis JB (1961) Determination of calcium and magnesium in urine by atomic absorption spectroscopy. Anal Chem 33: 556Google Scholar
  42. 42.
    Chiriboga J (1963) Some properties of an oxalic oxidase purified from barley seedlings. Biochem Biophys Res Commun 11: 277Google Scholar
  43. 43.
    Gruber W, Mollering H (1966) Citrat-Lyase und Bestimmung von Citrat. Biochem Z 346: 85Google Scholar
  44. 44.
    Fiske CH, Subbarow (1925) J Biol Chem 66: 375Google Scholar
  45. 45.
    Dryer RL, Routh JI (1963) Determination of serum inorganic phosphorous. Clin Chem 4: 191Google Scholar
  46. 46.
    Rock RC, Walker WG, Jennings CD (1986) Nitrogen metabolites and renal function. In: Tietz NW (ed) Textbook of clinical chemistry, vol 2. WB Saunders, Philadelphia p 1278Google Scholar
  47. 47.
    Fossati P, Prencipe L, Berti G (1980) Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 26: 227PubMedGoogle Scholar
  48. 48.
    Werness PG, Brown CM, Smith LH, Finlayson B (1985) EQUIL 2: a basic computer programme for the calculation of urinary saturation. J Urol 134: 1242PubMedGoogle Scholar
  49. 49.
    TiseliusHG (1982) An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122: 409PubMedGoogle Scholar
  50. 50.
    Ryall RL, Hibberd CM, Marshall VR (1985) A method for studying inhibitory activity in whole urine. Urol Res 12: 285Google Scholar
  51. 51.
    Ryall RL, Grover PK, Stapleton AMF, Barrell DK, Tang Y, Moritz RL et al. (1995) The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci 89: 533PubMedGoogle Scholar
  52. 52.
    Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH (1983) The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 130: 1115PubMedGoogle Scholar
  53. 53.
    Muldowney FP, Freaney R, Moloney MF (1982) Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 22: 292PubMedGoogle Scholar
  54. 54.
    Martini LA, Cuppari L, Cunha MA, Schor N, Heilberg IH (1998) Potassium and sodium intake and excretion in calcium stone forming patients. J Renal Nutr 8: 127Google Scholar
  55. 55.
    Pak CYC (1992) Citraturic response to oral citric acid load. J Urol 147: 975PubMedGoogle Scholar
  56. 56.
    Heller PC, Sakhaee K, Moe OW, Pal CYC (2002) Etiological role of estrogen status in renal stone formation. J Urol 168: 1923PubMedGoogle Scholar
  57. 57.
    Tiselius HG (1981) The effect of pH on the urinary inhibition of calcium oxalate crystal growth. Br J Urol 53: 470PubMedGoogle Scholar
  58. 58.
    Robson RH, Heading RC (1978) Obsolete but dangerous antacid preparations. Postgrad Med J 54: 36PubMedGoogle Scholar
  59. 59.
    Parfitt AM (1969) Acetozolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis. Arch Intern Med 124: 736PubMedGoogle Scholar
  60. 60.
    Pak CYC, Hayashi Y, Arnold LH (1976) Heterogeneous nucleation between urate, calcium phosphate and calcium oxalate. Proc Soc Exp Biol Med 153: 83PubMedGoogle Scholar
  61. 61.
    Pak CYC, Waters O, Arnold L, Holt K, Cox C, Barilla D (1977) Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest 59: 426PubMedGoogle Scholar
  62. 62.
    Hallson PC, Rose GA (1985) The additive effects of magnesium and tartrate upon inhibition of calcium oxalate formation in whole urine. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W (eds) Urolithiasis and related clinical research. Plenum Press, New York, p 847Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Department of ChemistryUniversity of Cape Town

Personalised recommendations